Synopsys, Rocket Companies, On Holding And A Health Care Stock On CNBC's 'Final Trades'
Gilead Sciences, Inc. GILD | 138.80 141.06 | -0.95% +1.63% Post |
On Holding AG Class A ONON | 32.21 33.08 | -4.34% +2.70% Post |
Rocket Companies, Inc. Class A RKT | 14.51 15.22 | -3.46% +4.89% Post |
Synopsys, Inc. SNPS | 397.90 409.00 | +0.21% +2.79% Post |
On CNBC's “Halftime Report Final Trades,” Hightower Advisors’ Stephanie Link picked Synopsys, Inc. (NASDAQ:SNPS) as her final trade.
Sunnyvale, California-based Synopsys is scheduled to report results for the first quarter on Wednesday, Feb. 25, after the closing bell.
Analysts expect the company to report quarterly earnings at $3.56 per share on revenue of $2.39 billion.
Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, said he likes Rocket Companies, Inc. (NYSE:RKT) right here.
Barclays analyst Terry Ma, on Jan. 6, maintained Rocket Companies with an Equal-Weight rating and raised the price target from $19 to $22.
Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ:GILD) as his final trade.
Lending support to his choice, Citigroup analyst Geoff Meacham, on Jan. 27, maintained a Buy rating on Gilead and raised the price target from $140 to $156, while Truist Securities analyst Gregory Renza maintained a Buy rating and boosted the price target from $140 to $145.
Don't forget to check out our premarket coverage here
Jim Lebenthal, partner at Cerity Partners, said On Holding AG (NYSE:ONON) will report earnings in a couple of earnings, and is expected to show great holiday sales.
BTIG analyst Janine Stichter, on Jan. 29, reiterated On Holding with a Buy rating and maintained a $70 price target.
Price Action:
- Rocket Companies shares dipped 13.7% to close at $17.93 on Friday.
- Gilead Sciences shares gained 1.7% to settle at $141.95 during the session.
- On Holding shares rose 0.8% to close at $45.25 on Friday.
- Synopsys shares fell 3.1% to settle at $465.11.
Image: Shutterstock